[go: up one dir, main page]

CL2019001066A1 - Sal de (s)-csa de s-ketamina, sal de (r)-csa de s-ketamina y procesos para la preparación de s-ketamina (divisional solicitud 201702854) - Google Patents

Sal de (s)-csa de s-ketamina, sal de (r)-csa de s-ketamina y procesos para la preparación de s-ketamina (divisional solicitud 201702854)

Info

Publication number
CL2019001066A1
CL2019001066A1 CL2019001066A CL2019001066A CL2019001066A1 CL 2019001066 A1 CL2019001066 A1 CL 2019001066A1 CL 2019001066 A CL2019001066 A CL 2019001066A CL 2019001066 A CL2019001066 A CL 2019001066A CL 2019001066 A1 CL2019001066 A1 CL 2019001066A1
Authority
CL
Chile
Prior art keywords
ketamine
salt
csa
processes
preparation
Prior art date
Application number
CL2019001066A
Other languages
English (en)
Inventor
Cheng Yi Chen
Oliver Floegel
Michael Justus
Adrian Maurer
Karl Reuter
Tobias Strittmatter
Tobias Wedel
Original Assignee
Janssen Pharmaceutica Nv
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Family has litigation
First worldwide family litigation filed litigation Critical https://patents.darts-ip.com/?family=56068863&utm_source=google_patent&utm_medium=platform_link&utm_campaign=public_patent_search&patent=CL2019001066(A1) "Global patent litigation dataset” by Darts-ip is licensed under a Creative Commons Attribution 4.0 International License.
Application filed by Janssen Pharmaceutica Nv filed Critical Janssen Pharmaceutica Nv
Publication of CL2019001066A1 publication Critical patent/CL2019001066A1/es

Links

Classifications

    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07C—ACYCLIC OR CARBOCYCLIC COMPOUNDS
    • C07C309/00—Sulfonic acids; Halides, esters, or anhydrides thereof
    • C07C309/01—Sulfonic acids
    • C07C309/02—Sulfonic acids having sulfo groups bound to acyclic carbon atoms
    • C07C309/23—Sulfonic acids having sulfo groups bound to acyclic carbon atoms of an unsaturated carbon skeleton containing rings other than six-membered aromatic rings
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07C—ACYCLIC OR CARBOCYCLIC COMPOUNDS
    • C07C309/00—Sulfonic acids; Halides, esters, or anhydrides thereof
    • C07C309/01—Sulfonic acids
    • C07C309/02—Sulfonic acids having sulfo groups bound to acyclic carbon atoms
    • C07C309/19—Sulfonic acids having sulfo groups bound to acyclic carbon atoms of a saturated carbon skeleton containing rings
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P11/00—Drugs for disorders of the respiratory system
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/04—Centrally acting analgesics, e.g. opioids
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/24—Antidepressants
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P9/00—Drugs for disorders of the cardiovascular system
    • A61P9/12—Antihypertensives
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07C—ACYCLIC OR CARBOCYCLIC COMPOUNDS
    • C07C225/00—Compounds containing amino groups and doubly—bound oxygen atoms bound to the same carbon skeleton, at least one of the doubly—bound oxygen atoms not being part of a —CHO group, e.g. amino ketones
    • C07C225/20—Compounds containing amino groups and doubly—bound oxygen atoms bound to the same carbon skeleton, at least one of the doubly—bound oxygen atoms not being part of a —CHO group, e.g. amino ketones having amino groups bound to carbon atoms of rings other than six-membered aromatic rings of the carbon skeleton
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07C—ACYCLIC OR CARBOCYCLIC COMPOUNDS
    • C07C303/00—Preparation of esters or amides of sulfuric acids; Preparation of sulfonic acids or of their esters, halides, anhydrides or amides
    • C07C303/32—Preparation of esters or amides of sulfuric acids; Preparation of sulfonic acids or of their esters, halides, anhydrides or amides of salts of sulfonic acids
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07B—GENERAL METHODS OF ORGANIC CHEMISTRY; APPARATUS THEREFOR
    • C07B2200/00—Indexing scheme relating to specific properties of organic compounds
    • C07B2200/07—Optical isomers
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07B—GENERAL METHODS OF ORGANIC CHEMISTRY; APPARATUS THEREFOR
    • C07B2200/00—Indexing scheme relating to specific properties of organic compounds
    • C07B2200/13—Crystalline forms, e.g. polymorphs
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07C—ACYCLIC OR CARBOCYCLIC COMPOUNDS
    • C07C2601/00—Systems containing only non-condensed rings
    • C07C2601/12—Systems containing only non-condensed rings with a six-membered ring
    • C07C2601/14—The ring being saturated
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07C—ACYCLIC OR CARBOCYCLIC COMPOUNDS
    • C07C2602/00—Systems containing two condensed rings
    • C07C2602/36—Systems containing two condensed rings the rings having more than two atoms in common
    • C07C2602/42—Systems containing two condensed rings the rings having more than two atoms in common the bicyclo ring system containing seven carbon atoms

Landscapes

  • Chemical & Material Sciences (AREA)
  • Organic Chemistry (AREA)
  • Health & Medical Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • General Health & Medical Sciences (AREA)
  • Veterinary Medicine (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • General Chemical & Material Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Engineering & Computer Science (AREA)
  • Animal Behavior & Ethology (AREA)
  • Public Health (AREA)
  • Biomedical Technology (AREA)
  • Neurology (AREA)
  • Neurosurgery (AREA)
  • Pain & Pain Management (AREA)
  • Heart & Thoracic Surgery (AREA)
  • Cardiology (AREA)
  • Psychiatry (AREA)
  • Pulmonology (AREA)
  • Acyclic And Carbocyclic Compounds In Medicinal Compositions (AREA)
  • Organic Low-Molecular-Weight Compounds And Preparation Thereof (AREA)

Abstract

LA PRESENTE INVENCIÓN ESTÁ DIRIGIDA A PROCESOS PARA LA PREPARACIÓN DE S-KETAMINA. LA PRESENTE INVENCIÓN ESTÁ DIRIGIDA, ADEMÁS, A PROCESOS PARA LA RESOLUCIÓN DE S-KETAMINA A PARTIR DE UNA MEZCLA RACÉMICA O ENANTIOMÉRICAMENTE ENRIQUECIDA DE KETAMINA. LA PRESENTE INVENCIÓN ESTÁ DIRIGIDA, ADEMÁS, A UNA SAL DE (S)-CSA DE S-KETAMINA, MÁS PARTICULARMENTE, UNA FORMA MONOHIDRATO DE LA SAL DE (S)-CSA DE S-KETAMINA; Y A UNA SAL DE (R)-CSA DE R-KETAMINA.
CL2019001066A 2015-05-13 2019-04-18 Sal de (s)-csa de s-ketamina, sal de (r)-csa de s-ketamina y procesos para la preparación de s-ketamina (divisional solicitud 201702854) CL2019001066A1 (es)

Applications Claiming Priority (1)

Application Number Priority Date Filing Date Title
US201562160659P 2015-05-13 2015-05-13

Publications (1)

Publication Number Publication Date
CL2019001066A1 true CL2019001066A1 (es) 2019-06-21

Family

ID=56068863

Family Applications (3)

Application Number Title Priority Date Filing Date
CL2017002854A CL2017002854A1 (es) 2015-05-13 2017-11-10 Sal de (s)-csa de s-ketamina, sal de (r)-csa de s-ketamina y procesos para la preparación de s-ketamin
CL2019001066A CL2019001066A1 (es) 2015-05-13 2019-04-18 Sal de (s)-csa de s-ketamina, sal de (r)-csa de s-ketamina y procesos para la preparación de s-ketamina (divisional solicitud 201702854)
CL2020001852A CL2020001852A1 (es) 2015-05-13 2020-07-13 Procesos de preparación de s-ketamina o clorhidrato de s-ketamina o productos derivados de éste. (divisional solicitud 201901066)

Family Applications Before (1)

Application Number Title Priority Date Filing Date
CL2017002854A CL2017002854A1 (es) 2015-05-13 2017-11-10 Sal de (s)-csa de s-ketamina, sal de (r)-csa de s-ketamina y procesos para la preparación de s-ketamin

Family Applications After (1)

Application Number Title Priority Date Filing Date
CL2020001852A CL2020001852A1 (es) 2015-05-13 2020-07-13 Procesos de preparación de s-ketamina o clorhidrato de s-ketamina o productos derivados de éste. (divisional solicitud 201901066)

Country Status (24)

Country Link
US (3) US20160332962A1 (es)
EP (1) EP3294704B1 (es)
JP (1) JP6882990B2 (es)
KR (1) KR102610047B1 (es)
CN (1) CN107750245B (es)
AU (1) AU2016260911B2 (es)
BR (1) BR112017024243B1 (es)
CA (1) CA2985696A1 (es)
CL (3) CL2017002854A1 (es)
CO (1) CO2017011553A2 (es)
CR (1) CR20170517A (es)
EA (1) EA201792503A1 (es)
EC (1) ECSP17075386A (es)
ES (1) ES2767708T3 (es)
GT (1) GT201700245A (es)
IL (1) IL255433B2 (es)
MX (1) MX377053B (es)
MY (1) MY181938A (es)
PE (1) PE20180527A1 (es)
PH (2) PH12017502024B1 (es)
SA (1) SA517390322B1 (es)
UA (1) UA121049C2 (es)
WO (1) WO2016180984A1 (es)
ZA (1) ZA201708417B (es)

Families Citing this family (19)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
SG10201802104QA (en) 2013-03-15 2018-05-30 Janssen Pharmaceutica Nv Pharmaceutical composition of s-ketamine hydrochloride
EP3179993B1 (en) 2014-08-13 2021-01-20 Janssen Pharmaceutica NV Esketamine for use in a method for the treatment of depression
US20160074340A1 (en) 2014-09-15 2016-03-17 Janssen Pharmaceutica Nv VAL66MET (SNP rs6265) GENOTYPE SPECIFIC DOSING REGIMENS AND METHODS FOR THE TREATMENT OF DEPRESSION
US20160332962A1 (en) 2015-05-13 2016-11-17 Janssen Pharmaceutica Nv (s)-csa salt of s-ketamine, (r)-csa salt of s-ketamine and processes for the preparation of s-ketamine
US20200009081A1 (en) 2017-09-13 2020-01-09 Janssen Pharmaceutica N.V. Delivery Of Esketamine For The Treatment Of Depression
US11707440B2 (en) 2017-12-22 2023-07-25 Janssen Pharmaceuticals, Inc. Esketamine for the treatment of depression
PL3505157T3 (pl) * 2017-12-29 2022-04-11 Celon Pharma S.A. Kompozycja ketaminy w postaci suchego proszku do podawania dopłucnego w leczeniu depresji opornej na leczenie
BR112020016500A2 (pt) 2018-02-15 2020-12-15 National University Corporation Chiba University Agente preventivo ou terapêutico e composição farmacêutica para doença inflamatória ou doença óssea
CN110218157B (zh) * 2018-03-01 2022-08-23 江苏恒瑞医药股份有限公司 一种r-氯胺酮及其可药用盐的制备方法
EP3813808A4 (en) 2018-05-04 2022-01-26 Perception Neuroscience, Inc. Methods of treating substance abuse
BR112020023882A2 (pt) 2018-06-27 2021-02-09 Clexio Biosciences Ltd. método para tratar transtorno depressivo maior
CN108659004B (zh) * 2018-07-12 2020-11-10 福安药业集团重庆博圣制药有限公司 奥拉西坦异构体的制备方法
EP3860579A1 (en) 2018-10-05 2021-08-11 Clexio Biosciences Ltd. Dosage regime of esketamine for treating major depressive disorder
BR112021017457A2 (pt) 2019-03-05 2021-11-16 Janssen Pharmaceuticals Inc Escetamina para o tratamento de depressão
EP3956300A1 (en) * 2019-04-16 2022-02-23 Janssen Pharmaceutica NV Synthetic methods of preparing esketamine
CN112375005A (zh) * 2019-08-16 2021-02-19 国药集团工业有限公司 一种氯胺酮、其衍生物或其盐的消旋化方法
US12268658B2 (en) 2019-12-30 2025-04-08 Clexio Biosciences Ltd. Dosage regime with esketamine for treating major depressive disorder
US12478592B2 (en) 2019-12-30 2025-11-25 Clexio Biosciences Ltd. Dosage regime with esketamine for treating neuropsychiatric or neurological conditions
WO2022208144A1 (en) * 2021-03-31 2022-10-06 Supriya Lifescience Ltd A crystalline form of 2-(2-chlorophenyl)-2-(methylamino) cyclohexanone hydrochloride and method thereof

Family Cites Families (39)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
CH535201A (de) * 1969-12-19 1973-03-31 Bristol Myers Co Verfahren zur Spaltung von racemischen 2-(o-Chlorphenyl)-2-methylaminocyclohexanon in die optisch-aktiven Isomeren
JPS5857420B2 (ja) * 1975-02-12 1983-12-20 ワコウジユンヤクコウギヨウ カブシキガイシヤ Ｄｌ− フエニルグリシンノ コウガクブンカツホウホウ
JPS632932A (ja) 1986-06-23 1988-01-07 Teijin Ltd 経鼻投与用粉末状組成物
JPS6314771A (ja) * 1986-07-08 1988-01-21 Sankyo Co Ltd 光学活性イミダゾ−ル誘導体およびその製法
JPS63192753A (ja) * 1987-02-05 1988-08-10 Otsuka Pharmaceut Co Ltd テトラヒドロキノリン誘導体の光学分割法
DE4312016A1 (de) 1993-04-13 1994-10-20 Goedecke Ag Stabile Ketamin-Lösungen
US5543434A (en) 1994-02-25 1996-08-06 Weg; Stuart L. Nasal administration of ketamine to manage pain
WO1996011894A1 (en) 1994-10-17 1996-04-25 Akzo Nobel N.V. Process for separating enantiomers from a racemic mixture
PE8798A1 (es) 1995-07-17 1998-03-02 Pfizer Procedimiento de separacion de los enantiomeros del 1-azabiciclo[2.2.2] octan-3-amina, 2-(difenilmetil) -n- [[2-metoxi-5-(1-metiletil) fenil] metil]
DE19619665C2 (de) * 1996-05-15 2001-03-08 Goedecke Ag Racemattrennung von Ketamin
TW430660B (en) * 1996-05-30 2001-04-21 Mochida Pharm Co Ltd Novel benzindole derivatives for neuron cell protection, processes for production, and the pharmaceutical compounds containing them
DE69924740T2 (de) 1998-07-24 2005-09-01 Yoo, Seo Hong Klare wässrige lösungen enthaltend gallensäuren
US6176242B1 (en) 1999-04-30 2001-01-23 Medtronic Inc Method of treating manic depression by brain infusion
EP1103256A1 (de) 1999-11-26 2001-05-30 Claudius Dr. med. Böck Verwendung von Ketamin zur Behandlung von neuroendokriner Immundysfunktion und algogenem Psychosyndrom
BRPI0002693B8 (pt) * 2000-06-19 2021-05-25 Cristalia Produtos Quim Farmaceuticos Ltda processo de obtenção dos enantiômeros da cetamina e seus sais farmaceuticamente aceitáveis
US7973043B2 (en) 2002-07-30 2011-07-05 Peter Migaly Combination therapy for depression, prevention of suicide, and various medical and psychiatric conditions
US7273889B2 (en) 2002-09-25 2007-09-25 Innovative Drug Delivery Systems, Inc. NMDA receptor antagonist formulation with reduced neurotoxicity
US7687080B2 (en) 2002-11-25 2010-03-30 Taraxos Inc. Treatment of neuropathy
US20040214215A1 (en) 2003-03-07 2004-10-28 Yu Ruey J. Bioavailability and improved delivery of alkaline pharmaceutical drugs
US20060276550A1 (en) 2005-06-03 2006-12-07 Dileep Bhagwat Topical compositions of ketamine and butamben and methods of their use
CN101466364A (zh) 2006-03-22 2009-06-24 纽约大学西奈山医学院 鼻内施用氯胺酮治疗抑郁症
EP2010544B1 (en) * 2006-04-21 2009-08-05 ZaCh System S.p.A. Process for preparing dorzolamide
EP2029136A4 (en) 2006-05-22 2010-01-06 Vanda Pharmaceuticals Inc TREATMENT FOR DEPRESSION DISEASES
DE102007009888A1 (de) 2007-02-28 2008-09-04 Hermann, Holger Lars, Dr. Verwendung von S-(+)-Ketamin zur Behandlung von Depressionen
US8710070B2 (en) * 2008-03-27 2014-04-29 University Of Kentucky Research Foundation Opioid-ketamine and norketamine codrug combinations for pain management
US20120225949A1 (en) 2009-08-14 2012-09-06 Demitri Papalos Compositions and methods for treating bipolar disorder
US20110038807A1 (en) 2009-08-14 2011-02-17 Demitri Papolos Compositions and methods for treating bipolar disorder
RU2589692C2 (ru) 2010-06-15 2016-07-10 Грюненталь Гмбх Фармацевтическая комбинация для лечения от боли
EP2780467B1 (en) 2011-11-14 2018-10-17 Alfasigma S.p.A. Assays and methods for selecting a treatment regimen for a subject with depression and methods for treatment
US9012486B2 (en) * 2011-11-14 2015-04-21 Alex Chervinsky Topical composition for pain relief
PE20141906A1 (es) 2012-03-12 2014-12-05 Janssen Pharmaceutica Nv Esketamina para el tratamiento de la depresion refractaria al tratamiento o resistente al tratamiento
US20140057988A1 (en) 2012-08-23 2014-02-27 Stuart WEG Anxiolytic composition, formulation and method of use
EP2903963A4 (en) * 2012-10-08 2016-05-25 Auckland Uniservices Ltd KETAMINE DERIVATIVES
SG10201802104QA (en) 2013-03-15 2018-05-30 Janssen Pharmaceutica Nv Pharmaceutical composition of s-ketamine hydrochloride
KR20230156807A (ko) 2013-03-15 2023-11-14 얀센 파마슈티카 엔브이 S-케타민 하이드로클로라이드의 약제학적 조성물
JP6462663B2 (ja) 2013-04-12 2019-01-30 アイカーン スクール オブ メディシン アット マウント シナイ 心的外傷後ストレス障害を処置するための方法
CA3143962A1 (en) * 2013-09-13 2015-03-19 National University Corporation Chiba University Application of r-ketamine and salt thereof as pharmaceuticals
US20160332962A1 (en) 2015-05-13 2016-11-17 Janssen Pharmaceutica Nv (s)-csa salt of s-ketamine, (r)-csa salt of s-ketamine and processes for the preparation of s-ketamine
US20160338977A1 (en) 2015-05-20 2016-11-24 Janssen Pharmaceutica Nv Methods and kits for treating depression

Also Published As

Publication number Publication date
US20210024461A1 (en) 2021-01-28
PE20180527A1 (es) 2018-03-19
IL255433B1 (en) 2023-03-01
CA2985696A1 (en) 2016-11-17
CL2020001852A1 (es) 2020-10-23
EP3294704A1 (en) 2018-03-21
PH12017502024B1 (en) 2023-04-05
CN107750245A (zh) 2018-03-02
IL255433A (en) 2018-02-28
IL255433B2 (en) 2023-07-01
AU2016260911A1 (en) 2017-11-16
GT201700245A (es) 2019-08-07
SA517390322B1 (ar) 2023-07-16
KR20180008568A (ko) 2018-01-24
MX377053B (es) 2025-03-07
MY181938A (en) 2021-01-14
HK1251546A1 (zh) 2019-02-01
US20180282266A1 (en) 2018-10-04
EP3294704B1 (en) 2019-10-30
CR20170517A (es) 2017-12-05
AU2016260911B2 (en) 2020-02-27
US10815196B2 (en) 2020-10-27
BR112017024243B1 (pt) 2021-12-07
KR102610047B1 (ko) 2023-12-05
BR112017024243A2 (pt) 2018-07-17
UA121049C2 (uk) 2020-03-25
CO2017011553A2 (es) 2018-04-19
JP2018516891A (ja) 2018-06-28
CN107750245B (zh) 2021-06-22
MX2017014473A (es) 2018-03-21
US20160332962A1 (en) 2016-11-17
EA201792503A1 (ru) 2018-02-28
ECSP17075386A (es) 2018-02-28
WO2016180984A1 (en) 2016-11-17
PH12021552213A1 (en) 2022-07-18
PH12017502024A1 (en) 2018-04-02
JP6882990B2 (ja) 2021-06-02
ES2767708T3 (es) 2020-06-18
CL2017002854A1 (es) 2018-04-20
ZA201708417B (en) 2018-11-28

Similar Documents

Publication Publication Date Title
CL2019001066A1 (es) Sal de (s)-csa de s-ketamina, sal de (r)-csa de s-ketamina y procesos para la preparación de s-ketamina (divisional solicitud 201702854)
EA201791420A1 (ru) Соединения триазолопиримидина и их применения
MX2018010427A (es) Formas solidas de un inhibidor de tienopirimidindiona acetil coa carboxilasa y metodos para su produccion.
EA201792354A1 (ru) Композиции обетихолевой кислоты и способы применения
AR105434A1 (es) Proceso para preparar pridopidina
EA201691582A1 (ru) Новые фармацевтические препараты
EA201692301A1 (ru) Производные бороновой кислоты и их терапевтическое применение
EA201691216A1 (ru) Композиции линаклотида с замедленным высвобождением
EA201890899A1 (ru) Модуляторы фарнезоидного x-рецептора
EA201690962A1 (ru) Составы
MX2017008136A (es) Sal de l-tartrato de pridopidina.
SV2018005621A (es) Inhibidor de la isocitrato deshidrogenasa mutada idh1 r132h
EA201791802A1 (ru) СШИТЫЕ ДИГИДРО-4H-ПИРАЗОЛО[5,1-c][1,4]ОКСАЗИНИЛОВЫЕ СОЕДИНЕНИЯ И АНАЛОГИ ДЛЯ ЛЕЧЕНИЯ ЗАБОЛЕВАНИЙ ЦНС
BR112017000135B8 (pt) Processo para a preparação de ácidos 4-alcóxi-3-hidroxipicolínico
EA201700356A1 (ru) Новые циклопропанбензофуранилпиридопиразиндионы
EA201791645A1 (ru) Новые соли и полиморфы scy-078
EA201591717A1 (ru) Твердые формы гидрохлорида вемурафениба
EA201691792A1 (ru) Фармацевтические составы на основе вилдаглиптина
AR100095A1 (es) Formas sólidas del ácido {[(2r,3s,4r,5s)-4-(4-cloro-2-fluoro-fenil)-3-(3-cloro-2-fluoro-fenil)-4-ciano-5-(2,2-dimetil-propil)-pirrolidin-2-carbonil]-amino}-3-metoxi-benzoico
MX384260B (es) Proceso para la preparacion de 3,7-dimetilnonan-1-ol.
MX2017004770A (es) Formas solidas del clorhidrato de nilotinib.
EA202190626A2 (ru) Комбинация тразодона и габапентина для лечения боли
EA201501177A1 (ru) Фармацевтические композиции
EA201890281A1 (ru) Новое применение сернокислых солей холекальциферола и новые сернокислые соли холекальциферола
MX2016017321A (es) Combinacicones y metodos para el tratamiento de dolor neuropatico.